NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
10 trialsNCT03044795 2024-05-03
REPAIR
University Medical Center Groningen
Phase 2 Withdrawn
NCT04774406 2023-06-06
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
University Hospital, Caen
Completed
NCT02723864 2022-02-08
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04774627 2021-09-23
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
University Hospital, Caen
Completed
NCT02032277 2021-01-20
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
AbbVie
Phase 3 Completed
NCT01445522 2019-12-17
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01853306 2017-11-21
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT00553189 2017-07-02
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01193140 2012-11-21
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
Abbott
Phase 2 Completed